What this means for you If you have Aetna Medicare Advantage, your current options are: Coverage for type 2 diabetes (Mounjaro may be covered) Coverage for moderate-to-severe OSA with BMI (body mass index) 27 (Medicare may cover unlike commercial Aetna) [12] Self-pay options: TrumpRx ($346/month), LillyDirect ($299-$449/month), or Foundayo (oral GLP-1, ~$149/month) Medicare GLP-1 Coverage Coming 2026 TrumpRx: Federal direct-to-consumer program launched February 6, 2026 offering Zepbound at ~$346/monthavailable to anyone including Medicare beneficiaries

Cardiovascular disease (CVD) is the main cause of death and disability among people with type 2 diabetes.[2] Adults with type 2 diabetes are two to four times more likely to develop CVD than adults without diabetes.[3] The FDA's decision on semaglutide is based on results from the SUSTAIN 6 cardiovascular outcomes trial (CVOT), which examined the cardiovascular safety of adding Ozempic or placebo to standard-of-care in adults with type 2 diabetes and established cardiovascular disease
So the theory is if we give that same signal, a hormone at a higher dose, we can overcome whatever that barrier is and it turned out to be true
Note: What you eat and drink How severe your symptoms are When the symptoms occur (e.g., after meals or medication) This information can help your doctor provide personalized advice or adjust your treatment plan if necessary
Additionally, semaglutide slows digestion, which can make people feel fuller and longer